Real World Molecular Testing In Patients With Egfr Mutation-Positive Locally Advanced Or Advanced Nsclc In Routine Practice In Germany - Interim Results Of The Clinical Registry Panorama

Introduction: Epidermal Growth Factor Receptor mutations (EGFRm) are among the most common in patients (pts) with non-small cell lung cancer (NSCLC) and can be targeted with EGFR tyrosine kinase inhibitors (TKIs). Appr. 50% of the pts will acquire resistance by the T790M mutation (T790M). Osimertinib (OSI) is a 3rd generation TKI and standard of care for pts who developed the acquired resistance by T790M during the prior TKI treatments, while other strategies, such as chemotherapy is used in T790M negative pts. Increasing evidence from both, clinical studies and registry data suggests that only the minority of patients can benefit from sequential TKI treatment with OSI.